Este sitio web utiliza tecnologías de seguimiento, como cookies, para brindar una mejor experiencia al usuario. Si continúa utilizando este sitio, entonces reconoce nuestro uso de tecnologías de seguimiento. Para obtener información adicional, consulte nuestra Política de Privacidad.
Glucose is an important energy source for our cancer-killing T cells. In kidney tumors, however, poor nutrient conditions often disrupt T cell metabolism and inhibit their anti-cancer activity. Dr. Beckermann is characterizing how exactly the tumor environment perturbs T cell metabolism. Then, using patients’ cells and mouse models, she’s developing approaches to support T cells and restore their normal metabolism. The insights she uncovers might then suggest ways to target and improve the effectiveness of these anti-cancer T cells in immunotherapies for patients.
Vanderbilt University | Breast Cancer, Kidney Cancer, Lung Cancer, Melanoma | 2016 | Jeffrey Rathmell, Ph.D.
*Los resultados de la inmunoterapia pueden variar de un paciente a otro.
Comuníquese con nosotros
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Directorio de Personal
Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.
Cancer is not “one-size-fits-all” and neither are its treatments, especially when it comes to immunotherapy. Learn how CRI is helping more people overcome cancer.